Literature DB >> 19052757

Criteria for the neuropathological diagnosis of dementing disorders: routes out of the swamp?

Kurt A Jellinger1.   

Abstract

There are several consensus criteria for both the clinical and neuropathological diagnosis of different types of dementias. The clinical diagnostic accuracy using revised research criteria and newly developed biomarkers (MRI, PET, CSF analysis, genetic markers) ranges from 65 to 96% (for Alzheimer disease) with a specificity of diagnostic criteria versus other dementias of 23-88%. Neuropathological assessment of dementing disorders using immunohistochemistry, molecular biologic and genetic methods can achieve a diagnosis/classification, based on the homogeneous definitions, harmonized inter-laboratory methods and standards for the assessment of nervous system lesions, in about 99%, without, however, being able to clarify the causes/etiology of most of these disorders. Further prospective and concerted clinicopathological studies using revised methodological and validated protocols and uniform techniques are required to establish the nature, distribution pattern and grades of lesions and; thus, to overcome the limitations of the current diagnostic framework. By data fusion this my allow their more uniform application and correlation with the clinical data in order to approach a diagnostic "gold standard", and to create generally accepted criteria for differentiating cognitive disorders from healthy brain aging. The detection of disease-specific pathologies will be indispensable to determinate the efficacy of new therapy options.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19052757     DOI: 10.1007/s00401-008-0466-z

Source DB:  PubMed          Journal:  Acta Neuropathol        ISSN: 0001-6322            Impact factor:   17.088


  22 in total

1.  Toward a pathological definition of vascular dementia.

Authors:  Lea Tenenholz Grinberg; Helmut Heinsen
Journal:  J Neurol Sci       Date:  2010-12-15       Impact factor: 3.181

Review 2.  Alzheimer's disease is not "brain aging": neuropathological, genetic, and epidemiological human studies.

Authors:  Peter T Nelson; Elizabeth Head; Frederick A Schmitt; Paulina R Davis; Janna H Neltner; Gregory A Jicha; Erin L Abner; Charles D Smith; Linda J Van Eldik; Richard J Kryscio; Stephen W Scheff
Journal:  Acta Neuropathol       Date:  2011-04-24       Impact factor: 17.088

3.  Beta-amyloid auto-antibodies are reduced in Alzheimer's disease.

Authors:  Bao-Xi Qu; Yunhua Gong; Carol Moore; Min Fu; Dwight C German; Ling-Yu Chang; Roger Rosenberg; Ramon Diaz-Arrastia
Journal:  J Neuroimmunol       Date:  2014-06-27       Impact factor: 3.478

4.  Accumulation of transactive response DNA binding protein 43 in mild cognitive impairment and Alzheimer disease.

Authors:  Cyntia Tremblay; Isabelle St-Amour; Julie Schneider; David A Bennett; Frédéric Calon
Journal:  J Neuropathol Exp Neurol       Date:  2011-09       Impact factor: 3.685

5.  Is AD a homogeneous nosologic entity? Yes.

Authors:  P Martinez-Martin
Journal:  J Neural Transm (Vienna)       Date:  2013-07-05       Impact factor: 3.575

Review 6.  [Visualization of amyloid with positron emission tomography. Useful improvement in the diagnosis of dementia?].

Authors:  T Grimmer; A Drzezga; A Kurz
Journal:  Nervenarzt       Date:  2010-05       Impact factor: 1.214

Review 7.  Alzheimer's disease as homeostatic responses to age-related myelin breakdown.

Authors:  George Bartzokis
Journal:  Neurobiol Aging       Date:  2009-09-22       Impact factor: 4.673

8.  Con: Can neuropathology really confirm the exact diagnosis?

Authors:  Kurt A Jellinger
Journal:  Alzheimers Res Ther       Date:  2010-05-07       Impact factor: 6.982

Review 9.  Neuropathological assessment of the Alzheimer spectrum.

Authors:  Kurt A Jellinger
Journal:  J Neural Transm (Vienna)       Date:  2020-08-01       Impact factor: 3.575

10.  Accumulation of neutral lipids in peripheral blood mononuclear cells as a distinctive trait of Alzheimer patients and asymptomatic subjects at risk of disease.

Authors:  Alessandra Pani; Antonella Mandas; Giacomo Diaz; Claudia Abete; Pier Luigi Cocco; Fabrizio Angius; Annalisa Brundu; Nico Muçaka; Maria Elena Pais; Antonio Saba; Luigi Barberini; Cristina Zaru; Manuela Palmas; Paolo F Putzu; Alessandra Mocali; Francesco Paoletti; Paolo La Colla; Sandra Dessì
Journal:  BMC Med       Date:  2009-11-02       Impact factor: 8.775

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.